Updates to Treatment of Recurrent Metastatic Head and Neck Cancers
Authors:
- Cristina P. RodriguezCRCristina P. Rodriguez
- Presented ByPBPresented By
- CloseCLClose
Open Access
- 1 May 2024
- journal article
- conference paper
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 22 (Supplement)
Abstract
The introduction of immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, has significantly improved overall survival in both the first- and second-line settings for patients with head and neck squamous cell carcinomas. In nasopharyngeal carcinomas, the combination of gemcitabine + cisplatin with PD-1 inhibitors has demonstrated impressive response rates and overall survival benefits. However, the unique immune-related adverse events associated with ICIs require patient counseling. Ongoing clinical trials are exploring novel combinations of ICIs with EGFR monoclonal antibodies, tyrosine kinase inhibitors, and therapeutic vaccines to further improve treatment outcomes. Biomarkers, such as circulating HPV-DNA and actionable molecular alterations (eg, HRAS mutations), may help guide treatment decisions and predict patient responses in the future.Keywords
This publication has 15 references indexed in Scilit:
- Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNature Medicine, 2023
- Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyJournal of Clinical Oncology, 2023
- Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.Journal of Clinical Oncology, 2022
- Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2022
- Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialThe Lancet Oncology, 2021
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell CarcinomaJournal of Clinical Oncology, 2014
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008